Cue Biopharma (CUE) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cue Biopharma (CUE) has outperformed Cartesian Therapeutics (RNAC) over the past year, losing 0.4% versus a loss of 30.1%. Over five years, CUE leads with a -92.7% price change compared with -94.5% for RNAC. Cartesian Therapeutics is the larger company by market cap ($213.5 million vs $200.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | RNAC |
|---|---|---|
| Share price | $27.66 | $7.06 |
| Market cap | $200.93M | $213.45M |
| 1-day change | +23.87% | +3.45% |
| YTD return | +202.30% | -2.15% |
| 1-year return | -0.43% | -30.15% |
| 5-year return | -92.68% | -94.49% |
| EPS (TTM) | $-29.59 | $-5.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $11.00 |
| 52-week low | $4.98 | $5.60 |
| Distance from 52-week high | -39.21% | -35.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.15% | +377.25% |
| Average volume | 266.83K | 133.51K |
| Shares outstanding | 7.26M | 30.26M |
| Employees | 29 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed RNAC by 29.7 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
CUE vs RNAC FAQ
Which is bigger, Cue Biopharma or Cartesian Therapeutics?
Cartesian Therapeutics (RNAC) is larger, with a market capitalization of $213.45M compared with $200.93M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or RNAC?
CUE returned -0.43% over the past 12 months, compared with -30.15% for RNAC (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.